Citations

Citations to this article as recorded by  

• Pharmacotherapy for obesity: moving towards efficacy improvement
  Walmir Coutinho, Bruno Halpern
  Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
• Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic
  Bruno Silvestrini, Mauro Silvestrini, Mayank Choubey
  Journal of Obesity.2024; 2024: 1.     CrossRef
• Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
  Yilin Li, Rong Lei, Honglin Lei, Qin Xiong, Fengjiao Xie, Chengjiao Yao, Peimin Feng
  European Journal of Gastroenterology & Hepatology.2023; 35(1): 1.     CrossRef
• Recommendations for the prevention and management of obesity in the Iraqi population
  Hussein Ali Nwayyir, Esraa Majid Mutasher, Osama Mohammed Alabid, Muthana Abdulrazzaq Jabbar, Wefak Hasan Abdulraheem Al-Kawaz, Haider Ayad Alidrisi, Majid Alabbood, Muhammed Chabek, Munib AlZubaidi, Lujain Anwar Al-khazrajy, Ibtihal Shukri Abd Alhaleem,
  Postgraduate Medicine.2023; 135(5): 425.     CrossRef
• A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
  Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman
  Life.2023; 13(4): 1012.     CrossRef
• Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
  Juyoung Shin, Raeun Kim, Hun-Sung Kim
  Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 49.     CrossRef
• The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
  Pejman Rohani, Nasser Malekpour Alamdari, Seyedeh Elaheh Bagheri, Azita Hekmatdoost, Mohammad Hassan Sohouli
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials
  Hao Gou, Yiman Zhai, Junjun Guo
  European Journal of Pediatrics.2023; 182(11): 5095.     CrossRef
• Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
  Ping Zhong, Hai Zeng, Miaochun Huang, Wenbin Fu, Zhixia Chen
  Endocrine.2022; 75(3): 718.     CrossRef
• Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
  David C. W. Lau, Rachel L Batterham, Carel W. le Roux
  Expert Review of Clinical Pharmacology.2022; 15(3): 251.     CrossRef
• Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine
  Peter Manu, Cristina-Mihaela Lăcătuşu, Liliana M. Rogozea, Simona Cernea
  American Journal of Therapeutics.2022; 29(4): e410.     CrossRef
• GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
  Katerina Horska, Jana Ruda-Kucerova, Silje Skrede
  Trends in Endocrinology & Metabolism.2022; 33(9): 628.     CrossRef
• Targeting skeletal muscle mitochondrial health in obesity
  Chantal A. Pileggi, Breana G. Hooks, Ruth McPherson, Robert R.M. Dent, Mary-Ellen Harper
  Clinical Science.2022; 136(14): 1081.     CrossRef
• A Study on Weight Loss Cause as per the Side Effect of Liraglutide
  Jin Yu, Jeongmin Lee, Seung-Hwan Lee, Jae-Hyung Cho, Hun-Sung Kim, Heng Zhou
  Cardiovascular Therapeutics.2022; 2022: 1.     CrossRef

Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which contributes to decreased postprandial glycemic excursions. In the 1990s, chronic subcutaneous infusion of GLP-1 was found to lower blood glucose levels in patients with type 2 diabetes. However, GLP-1's very short half-life, arising from cleavage by the enzyme dipeptidyl peptidase 4 (DPP-4) and glomerular filtration by the kidneys, presented challenges for clinical use. Hence, DPP-4 inhibitors were developed, as well as several GLP-1 analogs engineered to circumvent DPP-4-mediated breakdown and/or rapid renal elimination. Three categories of GLP-1 analogs, are being developed and/or are in clinical use: short-acting, long-acting, and prolonged-acting GLP-1 analogs. Each class has different plasma half-lives, molecular size, and homology to native GLP-1, and consequently different characteristic effects on glucose metabolism. In this article, we review current clinical data derived from each class of GLP-1 analogs, and consider the clinical effects reported for each category in recent head to head comparison studies. Given the relatively brief clinical history of these compounds, we also highlight several important efficacy and safety issues which will require further investigation.

Citations

Citations to this article as recorded by  

• The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
  Jhih-Syuan Liu, Sheng-Chiang Su, Feng-Chih Kuo, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Kuan-Chan Chen, Yi-Chen Liu, Chih-Ping Lin, An-Che Cheng, Chien-Hsing Lee, Fu-Huang Lin, Yi-Jen Hung, Hsin-Ya Liu, Chieh-Hua Lu, Chang-Hsun Hsieh
  Medicine.2023; 102(10): e33167.     CrossRef
• Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
  Mariya Kalinkova, Tanya Kadiyska, Teodora Handjieva-Darlenska
  Pharmacia.2023; 70(2): 383.     CrossRef
• Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation
  Irem Mert, Ayhan Cetinkaya, Mujgan Gurler, Canan Akünal Turel, Humeyra Celik, Ibrahim Ethem Torun, Idris Turel
  Inflammopharmacology.2022; 30(3): 1093.     CrossRef
• Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
  Chuanmin Bai, Yujun Wang, Zhi Niu, Yaxin Guan, Jingshan Huang, Xin Nian, Fan Zuo, Juan Zhao, Tsutomu Kazumi, Bin Wu
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
  Hun Jee Choe, Young Min Cho
  Endocrinology and Metabolism.2021; 36(1): 22.     CrossRef
• Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice
  Xingchun Wang, Bingwei Ma, Jiaqi Chen, Hui You, Chunjun Sheng, Peng Yang, Shen Qu, Vito Angelo Giagulli
  International Journal of Endocrinology.2021; 2021: 1.     CrossRef
• Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin
  Zeinab A. Saad, Dina M. Khodeer, Sawsan A. Zaitone, Amal A.M. Ahmed, Yasser M. Moustafa
  Life Sciences.2020; 253: 117725.     CrossRef
• Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
  Shan Li, Xiaoman Wang, Jielei Zhang, Jingyi Li, Xiaogang Liu, Yuanyuan Ma, Chao Han, Lixia Zhang, Lili Zheng
  Brazilian Journal of Medical and Biological Research.2018;[Epub]     CrossRef
• Efficacy and safety of combination therapy with an α‐glucosidase inhibitor and a dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta‐analysis
  Se Hee Min, Jeong‐Hwa Yoon, Seokyung Hahn, Young Min Cho
  Journal of Diabetes Investigation.2018; 9(4): 893.     CrossRef
• Glucagon-like peptide-1 affects human umbilical vein endothelial cells in high glucose by the PI3K/Akt/eNOS signaling pathway
  Jie Wu, Pingfan Guo, Tianmin He, Fanggang Cai
  Turkish Journal of Biochemistry.2018; 43(2): 119.     CrossRef
• What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus
  Wing B. Chan, Andrea Luk, Wing S. Chow, Vincent T.F. Yeung
  Journal of Diabetes.2017; 9(6): 562.     CrossRef
• Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
  L. Østergaard, Christian S. Frandsen, S. Madsbad
  Expert Review of Clinical Pharmacology.2016; 9(2): 241.     CrossRef
• Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
  Johan Jendle, George Grunberger, Thomas Blevins, Francesco Giorgino, Ryan T. Hietpas, Fady T. Botros
  Diabetes/Metabolism Research and Reviews.2016; 32(8): 776.     CrossRef
• Glucagon‐like peptide‐1(GLP‐1) receptor agonists: potential to reduce fracture risk in diabetic patients?
  Guojing Luo, Hong Liu, Hongyun Lu
  British Journal of Clinical Pharmacology.2016; 81(1): 78.     CrossRef
• Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?
  Sten Madsbad
  Journal of Diabetes and its Complications.2016; 30(2): 374.     CrossRef
• Risk assessment and management of post-transplant diabetes mellitus
  Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
  Metabolism.2016; 65(10): 1559.     CrossRef
• Recent advances in oral delivery of peptide hormones
  Pegah Varamini, Istvan Toth
  Expert Opinion on Drug Delivery.2016; 13(4): 507.     CrossRef
• Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
  Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
  PLOS ONE.2016; 11(12): e0166913.     CrossRef
• Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
  Sten Madsbad
  Diabetes, Obesity and Metabolism.2016; 18(4): 317.     CrossRef
• Does Bosentan Protect Diabetic Brain Alterations in Rats? The Role of Endothelin‐1 in the Diabetic Brain
  Recep Demir, Elif Cadirci, Erol Akpinar, Yasemin Cayir, Hasan Tarik Atmaca, Harun Un, Celalettin Semih Kunak, Muhammed Yayla, Zafer Bayraktutan, Ilknur Demir
  Basic & Clinical Pharmacology & Toxicology.2015; 116(3): 236.     CrossRef
• Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
  P. D. Home, P. Shamanna, M. Stewart, F. Yang, M. Miller, C. Perry, M. C. Carr
  Diabetes, Obesity and Metabolism.2015; 17(2): 179.     CrossRef
• Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
  Jaime A. Davidson
  Postgraduate Medicine.2015; 127(8): 827.     CrossRef
• GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
  Jia Liu, Guang Wang, Yumei Jia, Yuan Xu
  Diabetes/Metabolism Research and Reviews.2015; 31(4): 329.     CrossRef
• Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial
  M. K. Kim, E.‐J. Rhee, K. A. Han, A. C. Woo, M.‐K. Lee, B. J. Ku, C. H. Chung, K.‐A. Kim, H. W. Lee, I. B. Park, J. Y. Park, H. C. Chul Jang, K. S. Park, W. I. Jang, B. Y. Cha
  Diabetes, Obesity and Metabolism.2015; 17(3): 309.     CrossRef
• Incretin physiology and pathophysiology from an Asian perspective
  Young Min Cho
  Journal of Diabetes Investigation.2015; 6(5): 495.     CrossRef
• Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J2015;39:74-81)
  Antoni Sicras-Mainar, Ruth Navarro-Artieda
  Diabetes & Metabolism Journal.2015; 39(2): 173.     CrossRef
• Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
  Se Hee Min, Young Min Cho
  The Journal of Korean Diabetes.2015; 16(4): 252.     CrossRef
• Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells
  Min Joo Kim, Ok Kyong Choi, Kyung Sil Chae, Hakmo Lee, Sung Soo Chung, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung
  Islets.2015; 7(5): e1129096.     CrossRef
• Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
  Mi Yeon Kang, Tae Jung Oh, Young Min Cho
  Endocrinology and Metabolism.2015; 30(2): 216.     CrossRef
• Interleukin-6 CpG Methylation and Body Weight Correlate Differently in Type 2 Diabetes Patients Compared to Obese and Lean Controls
  Eva Aumueller, Marlene Remely, Hanna Baeck, Berit Hippe, Helmut Brath, Alexander G. Haslberger
  Lifestyle Genomics.2015; 8(1): 26.     CrossRef
• The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells
  Hirohisa Onuma, Kouichi Inukai, Atsuko Kitahara, Rie Moriya, Susumu Nishida, Toshiaki Tanaka, Hidenori Katsuta, Kazuto Takahashi, Yoshikazu Sumitani, Toshio Hosaka, Hitoshi Ishida
  Biochemical and Biophysical Research Communications.2014; 451(2): 339.     CrossRef
• Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
  Won-Young Lee
  Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
• Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone
  Dorit Naot, Jillian Cornish
  Frontiers in Endocrinology.2014;[Epub]     CrossRef
• Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
  Maria Voukali, Irene Kastrinelli, Sapfo Stragalinou, Dimitra Tasiopoulou, Pinelopi Paraskevopoulou, Nicholas Katsilambros, Alexandros Kokkinos, Nicholas Tentolouris, Ioannis Ioannidis
  Journal of Diabetes Research.2014; 2014: 1.     CrossRef
• The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?
  Mark F McCarty, James J DiNicolantonio
  Open Heart.2014; 1(1): e000103.     CrossRef
• Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad
  J.J. Gorgojo-Martínez
  Hipertensión y Riesgo Vascular.2014; 31(2): 45.     CrossRef
• Managing Loss of Glycemic Control in Middle-Aged Patients With Diabetes: The Role of GLP-1 Receptor Agonists in Combination-Therapy Regimens
  Thomas B. Repas
  Journal of Osteopathic Medicine.2014; 114(s52): 14.     CrossRef